Antiviral Drug Side Effects May Trigger Other Types of Hepatitis, European Regulators Warn

Certain antiviral drugs used to treat hepatitis C may cause a reactivation of hepatitis B, according to new warnings issued by European health officials. 

The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) issued a warning on December 2, indicating patients who take direct-acting antivirals to treat hepatitis C may face an increased risk of reactivating latent hepatitis B.

Health officials warned patients who had hepatitis B in the past and are now taking certain direct-acting antivirals to treat hepatitis C infection are at risk of having the hepatitis B virus reactivate.

Did You Know?

AT&T Data Breach Impacts Millions of Customers

More than 73 million customers of AT&T may have had their names, addresses, phone numbers, Social Security numbers and other information released on the dark web due to a massive AT&T data breach. Lawsuits are being pursued to obtain financial compensation.

Learn More

So far, at least 30 cases of hepatitis B reactivation have been reported in Europe. The direct-acting antiviral drugs are marketed in the European Union as Daklinza, Exviera, Harvoni, Olysio, Sovaldi, and Viekirax.

The announcement follows an FDA advisory issued in October, which indicated that a black box warning would be added to hepatitis C direct-acting antivirals in the U.S. The FDA warned that the drugs could reactivate hepatitis B in patients with both viruses, indicating that the agency had received at least 24 reports of hepatitis B reactivation after patients began using the drugs.

The antiviral medications are used to treat chronic long-term hepatitis C; an inflammation of the liver caused by the hepatitis C virus, at times also caused by drug or alcohol abuse, infections or autoimmune disease. The drugs help to control and sometimes cure the hepatitis C virus, preventing liver problems like cancer, cirrhosis and death.

Data also indicates there is a lack of evidence suggesting the direct-acting antivirals can treat liver cancer in patients. The agency said it concluded “further studies should be carried out before firm conclusions can be draw” pertaining to liver cancer treatment.

The agency suggests the rapid-treatment reducing the hepatitis C virus may re-trigger the hepatitis B virus, which can be fatal.

While reactivation frequency of hepatitis B is low, PRAC calls for a warning to be included in the mediation prescribing information. PRAC also announced a recommendation to forward its recommendations to the Committee for Medicinal Products for Human Use for a final decision.

The PRAC warning recommended hepatitis C infected patients should be screened for the hepatitis B virus before starting treatment with any direct-acting antivirals. Patients infected with both viruses should be monitored and current medical guidelines should be followed.

1 Comments

  • CJMarch 21, 2017 at 5:06 am

    Since taking Sovaldi and Daklinza my health continues to deteriorate. I have went from 174 lbs to 123 lbs and continue to lose weight. I have lost all muscle mass.

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Uber Driver Sexual Assaults and Misconduct Reports Must Be Disclosed in Lawsuit Discovery
Uber Driver Sexual Assaults and Misconduct Reports Must Be Disclosed in Lawsuit Discovery (Posted today)

A federal magistrate judge is forcing Uber to hand over potentially hundreds of thousands of incident files involving reports of passengers who suffered sexual misconduct or sexual assault at the hands of the rideshare service's drivers.

Abbott May Remove Infant Formula for Preemies Off the Market Due to Similac NEC Lawsuits
Abbott May Remove Infant Formula for Preemies Off the Market Due to Similac NEC Lawsuits (Posted yesterday)

Abbott Laboratories is considering removing Similac infant formula products designed for preterm babies from the market, as it faces hundreds of lawsuits claiming the products increase the risk of necrotizing enterocolitis, which puts newborns at a high risk of permanent injuries and death.

Information About Suboxone Dental Claims To Be Exchanged By Parties in MDL
Information About Suboxone Dental Claims To Be Exchanged By Parties in MDL (Posted 2 days ago)

A federal judge has ordered parties involved in Suboxone dental decay lawsuits to submit proposals for exchanging information that will guide the selection of representative bellwether claims for early test trials.